In Vitro and In Vivo Efficacy of Romidepsin Alone and in Addition to Standard of Care for Treatment of Ewing Sarcoma
Kaitlyn H. Smith, Erin M. Trovillion, Kimberly Q. McKinney, Poornima Gourabathini, Kenzie Wells, Divya Gandra, Chloe Sholler, Ingrid Votruba, Javier Oesterheld, Giselle L. Saulnier Sholler · 2025
Read In Vitro and In Vivo Efficacy of Romidepsin Alone and in Addition to Standard of Care for Treatment of Ewing Sarcoma by Kaitlyn H. Smith, Erin M. Trovillion, Kimberly Q. McKinney, Poornima Gourabathini, Kenzie Wells, Divya Gandra, Chloe Sholler, Ingrid Votruba, Javier Oesterheld, Giselle L. Saulnier Sholler (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12730613.txt.
Description
Kaitlyn Smith and co-authors test a gene regulating drug against Ewing sarcoma in cells and animals, in a study from 2025. This aggressive cancer, mostly of children and young adults, badly needs better treatments. A family of enzymes that loosen DNA packing helps drive the tumor, and blocking them is a promising line of attack.
Several blocking drugs were screened against tumor cell lines, and one, romidepsin, came out strongest. Protein tests showed it switched off machinery for cell division and DNA repair. In dishes it also boosted the effect of standard chemotherapy drugs. The team then moved the tests into living models, alone and beside standard care. The results build a case for trying the drug in patients.
Catalog record
| CREATOR | Kaitlyn H. Smith, Erin M. Trovillion, Kimberly Q. McKinney, Poornima Gourabathini, Kenzie Wells, Divya Gandra, Chloe Sholler, Ingrid Votruba, Javier Oesterheld, Giselle L. Saulnier Sholler |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 24 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |